Drake W P, Mardiney M R
J Immunol. 1975 Mar;114(3):1052-7.
The simultaneous injection of heterologous anti-EL4 lymphoma serum and complement results in the rapid disappearance of such antibody from the periphery of non-tumor bearing mice. However, this phenomenon is only observed when a complement source capable of mediating the lysis of EL4 cells sensitized with such heterologous antibody is used. This complement mediated enhancement of anti-tumor antibody absorption was observed in vivo for three strains of mice. Omission of complement or the use of genetically deficient complement sources resulted in no effect on circulating antibody titer when compared to the titer of heterologous anti-tumor antibody observed in the periphery when injected alone. Exogenous complement did not enhance the clearance of heterologous anti-tetanus toxin serum, thereby suggesting that the increased absorption of anti-EL4 in vivo is not related simply to the enhanced clearance of foreign gamma-globulin. Confirmatory evidence of the role of complement in altering anti-tumor antibody specificity in vivo was obtained in a guinea pig tumor model as well. The data suggest that anti-tumor serum shown to be relatively specific for the tumor cell gains additional specificity in the presence of functional complement and consequently manifests avidity for cross-reactive determinants previously thought to be unrelated.
同时注射异种抗 EL4 淋巴瘤血清和补体，会导致这种抗体在未荷瘤小鼠外周迅速消失。然而，只有当使用能够介导被这种异种抗体致敏的 EL4 细胞裂解的补体来源时，才会观察到这种现象。在三种小鼠品系中均在体内观察到了这种补体介导的抗肿瘤抗体吸收增强现象。与单独注射时在外周观察到的异种抗肿瘤抗体滴度相比，省略补体或使用基因缺陷的补体来源对循环抗体滴度没有影响。外源性补体并未增强异种抗破伤风毒素血清的清除，从而表明体内抗 EL4 抗体吸收增加并非仅仅与外来γ球蛋白清除增强有关。在豚鼠肿瘤模型中也获得了补体在体内改变抗肿瘤抗体特异性作用的证实性证据。数据表明，显示对肿瘤细胞相对特异的抗肿瘤血清在功能性补体存在的情况下获得了额外的特异性，因此表现出对先前认为无关的交叉反应性决定簇的亲和力。
